SIC
TARA icon

SJS Investment Consulting’s Protara Therapeutics TARA Stock Holding History

SJS Investment Consulting’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77 Buy
20
+12
+150% +$57 ﹤0.01% 2656
2026
Q1 		$42 Buy
+8
New +$47 ﹤0.01% 2274

Other funds holding TARA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

SJS Investment Consulting's TARA Position: Q2 2026 in Review

SJS Investment Consulting increased its Protara Therapeutics (TARA) stake by 150% in Q2 2026, buying an estimated $57 and bringing the position to 20 shares worth $77. The position accounts for ﹤0.01% of the portfolio, ranked #2656.

SJS Investment Consulting first reported a position in TARA in Q1 2026 and has held it in 2 quarters since. 42 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • SJS Investment Consulting held 20 shares of Protara Therapeutics worth $77 as of Q2 2026.
  • SJS Investment Consulting bought 12 Protara Therapeutics shares in Q2 2026, an estimated $57.
  • Protara Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2656 holding.
  • SJS Investment Consulting first reported a position in Protara Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 42 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.